REFLECTIONS OF A PHARMACIST, ACADEMIC AND RESEARCHER IN A PIVOTAL YEAR OF CHANGE FOR THE PHARMACY PROFESSION
Dr Kate Wang, Senior Lecturer in Pharmacy, RMIT University &
Adjunct Senior Lecturer, University of Western Australia
PEOPLE IN HEALTH CARE
Filmed in Melbourne, Victoria | December 2024
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
With Australia’s ageing population projected to reach 21-23% of those over 65 by 2060, the need for effective medication management is crucial. Older adults often face multiple chronic conditions and take multiple medications, making pharmacists essential as medication experts.
Pharmacists are the most accessible healthcare professionals in Australia, allowing for regular patient interactions. This consistent contact enables them to provide ongoing monitoring and health management, highlighting the importance of expanding their scope of practice. Dr. Wang emphasises the trialing of structured prescribing for conditions like uncomplicated urinary tract infections and oral contraceptives, where timely access is vital.
Attending the PSA24 conference hosted by the Pharmaceutical Society of Australia in Sydney, she noted the collaborative efforts among healthcare professionals to address changes in scope of practice. The process requires thorough review and piloting, with a commitment to patient centred care. As the field evolves, pharmacists must adapt to new treatments and emerging health challenges, continuously striving to make a positive impact on individuals and the broader community.
You Might also like
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
-
Research funded to investigate early-onset bowel cancer progression
Bowel Cancer Australia recently announced a team led by Professor Michael Samuel as the successful applicant for a three-year $600k early-onset bowel cancer research project through the 2023 round of Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).